Literature DB >> 417671

Comparison of ticarcillin and carbenicillin activity against random and select populations Pseudomonas aeruginosa.

R B Prior, R J Fass.   

Abstract

The in vitro activities of ticarcillin (T) and carbenicillin (C) against 253 strains of Pseudomonas aeruginosa (108 randomly selected clinical isolates and 145 isolates determined to be C resistant by 10 referring hospitals) were evaluated using both broth microdilution and disk diffusion techniques. T activity was usually twofold or greater than C activity for individual strains in both sample populations. The minimal inhibitory concentration (MIC) values of T and C were </=0.4 to >400 (median, 25) and 0.8 to >400 (median, 50) mug/ml, respectively, for the random sample and 1.6 to >400 (median, 50) and 12.5 to >400 (median, 200) mug/ml, respectively, for the select sample. For predicting susceptibility (MIC, </=50 mug of T and </=100 mug of C per ml), 75-mug T and 100-mug C disks were equivalent in accuracy for the random sample (T/T = 92.6%, T/C = 92.0%, C/T = 91.7%, C/C = 89.8%). Regression-line analyses of zones of inhibition versus MIC values for the four combinations showed coefficients of correlation to be -0.81, -0.76, -0.77, and -0.75, respectively. With the sample selected as being resistant to C, T was better than C for predicting T susceptibility (P < 0.05), and T was equivalent to C for predicting C susceptibility (T/T = 84.3%, T/C = 81.0%, C/T = 73.6%, C/C = 80.4%). Coefficients of correlation were -0.70, -0.74, -0.55, and -0.61, respectively. T and C disks were, therefore, equivalent for determining T and C susceptibilities, but the T disk was more reliable for determining T susceptibility in a population skewed with C-resistant strains.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 417671      PMCID: PMC352211          DOI: 10.1128/AAC.13.2.184

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  6 in total

1.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

2.  Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin.

Authors:  H C Neu; G J Garvey
Journal:  Antimicrob Agents Chemother       Date:  1975-10       Impact factor: 5.191

3.  Comparison and evaluation of ticarcillin and carbenicillin using disk diffusion methods.

Authors:  M F Parry; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1976-04       Impact factor: 5.191

4.  Comparative in vitro evaluation of the effects of ticarcillin and carbenicillin upon Psuedomonas aeruginosa.

Authors:  E Kalkani; N Marketos
Journal:  Antimicrob Agents Chemother       Date:  1976-01       Impact factor: 5.191

5.  Semisynthetic penicillin 6-(D(--)-alpha-carboxy-3-thienylacetamido) penicillanic acid active against Pseudomonas in vitro.

Authors:  H C Neu; E B Winshell
Journal:  Appl Microbiol       Date:  1971-01

6.  In vitro studies of alpha-carboxyl-3-thienylmethyl penicillin, a new semisynthetic penicillin.

Authors:  G P Bodey; B Deerhake
Journal:  Appl Microbiol       Date:  1971-01
  6 in total
  4 in total

1.  Proposed ticarcillin disk control values for Escherichia coli and Pseudomonas aeruginosa: multicenter cooperative study.

Authors:  R B Prior; R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1978-09       Impact factor: 5.191

2.  Pseudomonas endophthalmitis associated with scleral necrosis.

Authors:  K H Tarr; I J Constable
Journal:  Br J Ophthalmol       Date:  1980-09       Impact factor: 4.638

3.  Pseudomonas denitrificans meningitis.

Authors:  R A Fischer; G V Doern; S H Cheeseman
Journal:  J Clin Microbiol       Date:  1981-05       Impact factor: 5.948

4.  Statistical comparison of the antibacterial activities of broad-spectrum penicillins against gram-negative bacilli.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.